Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma

Yi,Huo‑Chun; Liu,Ya‑Li; You,Pan; Pan,Jin‑Shui; Zhou,Jian‑Yan; Liu,Zhen‑Jin; Zhang,Zhong-Ying

doi:10.3892/mmr.2014.2781

Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma

Authors:
- Huo‑Chun Yi
- Ya‑Li Liu
- Pan You
- Jin‑Shui Pan
- Jian‑Yan Zhou
- Zhen‑Jin Liu
- Zhong-Ying Zhang
View Affiliations

Affiliations: Center of Clinical Laboratory, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Thoracic Surgery, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Gastroenterology, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Hepatobiliary Surgery, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Pathology, Zhongshan Hospital, Medical College of Xiamen University, Xiamen, Fujian 361004, P.R. China
Published online on: October 27, 2014 https://doi.org/10.3892/mmr.2014.2781
Pages: 1318-1323

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The oncogene DEK was originally identified as one of the parts of the DEK‑CAN fusion gene, arising from the translocation (6;9) in a subtype of acute myeloid leukemia. Since then, DEK has been shown to promote tumorigenesis in a variety of cancer cell types through its roles in inhibiting cell differentiation, senescence and apoptosis. Certain studies have established that DEK is dysregulated in several types of cancer, including hepatocellular carcinoma (HCC). However, its clinical significance in human HCC remains unknown. In this study, the expression of DEK mRNA and protein was examined in 55 surgical HCC specimens and matched non‑tumorous tissues. In addition, the correlation between DEK expression and clinicopathological characteristics and prognosis was analyzed. mRNA and protein levels of DEK were found to be significantly overexpressed in the majority of HCC tumors when compared with matched normal hepatic tissues (P<0.05). In addition, the expression pattern of DEK was closely correlated with differentiation status, portal venous invasion and tumor size (P<0.05). Kaplan‑Meier curves demonstrated that patients with higher DEK expression levels had significantly poorer survival than those with lower DEK expression levels (P=0.003). In addition, Cox regression analysis demonstrated that the level of DEK expression may be a valuable prognostic factor (P<0.05). These results suggested that DEK may play a significant role in hepatocyte differentiation and may serve as a useful prognostic marker and biomarker for the staging of HCC.

View Figures

View References

1	Murray CJ and Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 349:1269–1276. 1997. View Article : Google Scholar : PubMed/NCBI
2	Sakamoto M: Pathology of early hepatocellular carcinoma. Hepatol Res. 37(Suppl 2): S135–S138. 2007. View Article : Google Scholar : PubMed/NCBI
3	Tung-Ping Poon R, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 232:10–24. 2000. View Article : Google Scholar : PubMed/NCBI
4	von Lindern M, Fornerod M, van Baal S, et al: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol. 12:1687–1697. 1992.PubMed/NCBI
5	Carro MS, Spiga FM, Quarto M, et al: DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
6	Lü ZL, Luo DZ and Wen JM: Expression and significance of tumor-related genes in HCC. World J Gastroenterol. 11:3850–3854. 2005.PubMed/NCBI
7	Kappes F, Khodadoust MS, Yu L, et al: DEK expression in melanocytic lesions. Hum Pathol. 42:932–938. 2011. View Article : Google Scholar : PubMed/NCBI
8	Khodadoust MS, Verhaegen M, Kappes F, et al: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zheng J, Kohler ME, Chen Q, et al: Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol. 8:42007. View Article : Google Scholar : PubMed/NCBI
10	Datta A, Adelson ME, Mogilevkin Y, et al: Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 11:2342011. View Article : Google Scholar : PubMed/NCBI
11	Wise-Draper TM, Morreale RJ, Morris TA, et al: DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol. 174:71–81. 2009. View Article : Google Scholar :
12	Liu S, Wang X, Sun F, et al: DEK overexpression is correlated with the clinical features of breast cancer. Pathol Int. 62:176–181. 2012. View Article : Google Scholar : PubMed/NCBI
13	Abba MC, Sun H, Hawkins KA, et al: Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res. 5:881–890. 2007. View Article : Google Scholar : PubMed/NCBI
14	Privette Vinnedge LM, McClaine R, Wagh PK, et al: The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 30:2741–2752. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kondoh N, Wakatsuki T, Ryo A, et al: Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59:4990–4996. 1999.PubMed/NCBI
16	Lin LJ and Chen LT: The role of DEK protein in hepatocellular carcinoma for progression and prognosis. Pak J Med Sci. 29:778–782. 2013. View Article : Google Scholar : PubMed/NCBI
17	Edmondson H and Steiner P: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
18	Sitwala KV, Adams K and Markovitz DM: YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene. 21:8862–8870. 2002. View Article : Google Scholar : PubMed/NCBI
19	Hu HG, Scholten I, Gruss C and Knippers R: The distribution of the DEK protein in mammalian chromatin. Biochem Biophys Res Commun. 358:1008–1014. 2007. View Article : Google Scholar : PubMed/NCBI
20	Grasemann C, Gratias S, Stephan H, et al: Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene. 24:6441–6449. 2005.PubMed/NCBI
21	Evans AJ, Gallie BL, Jewett MA, et al: Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol. 164:285–293. 2004. View Article : Google Scholar
22	Castellano G, Torrisi E, Ligresti G, et al: The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle. 8:1367–1372. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wise-Draper TM, Mintz-Cole RA, Morris TA, et al: Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res. 69:1792–1799. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wise-Draper TM, Allen HV, Jones EE, et al: Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol. 26:7506–7519. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wise-Draper TM, Allen HV, Thobe MN, et al: The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol. 79:14309–14317. 2005. View Article : Google Scholar : PubMed/NCBI